Iron-Powered Cell Death Emerges as Double-Edged Sword in Cancer’s Microenvironment

Cancer cells live dangerously. Their metabolism churns through iron and fat at a pace that leaves their membranes studded with fragile, easily oxidized lipids, and when those lipids finally succumb to peroxidation, the cell dies in a violent, iron-dependent collapse known as ferroptosis. Since the pathway was formally named in 2012, researchers have hoped that this vulnerability could be weaponized against tumors that shrug off chemotherapy, radiotherapy, and even modern immunotherapies. A new review published in Medical Oncology by Mohammad Fahad Ullah of the University of Tabuk synthesizes the rapidly expanding literature and arrives at a sobering but nuanced conclusion: ferroptosis is not simply an on-off switch that clinicians can flip. Its behavior depends intimately on the tumor microenvironment, the crowded ecosystem of fibroblasts, immune cells, blood vessels, and signaling molecules that surrounds every tumor, and that ecosystem can either amplify the lethal lipid peroxidation or quietly extinguish it.

The biochemistry of ferroptosis is now mapped in considerable detail. At its center sits the system Xc⁻/glutathione/glutathione peroxidase 4 axis, a cellular antioxidant circuit in which the cystine-glutamate antiporter imports cysteine that fuels glutathione synthesis, and GPX4 uses that antioxidant reservoir to detoxify lipid hydroperoxides in membranes. Block the importer, deplete glutathione, or inhibit GPX4 directly, and lipid peroxides accumulate until membranes rupture. Iron metabolism supplies the spark: transferrin receptor 1 imports iron, ferritin stores it, and the autophagic degradation of ferritin, termed ferritinophagy, releases labile iron that catalyzes the Fenton chemistry driving peroxide formation. Lipid remodeling determines which membranes are flammable. The enzyme ACSL4 channels polyunsaturated fatty acids into phospholipids, making cells rich in ACSL4 exquisitely sensitive, while parallel suppressors such as FSP1 and endogenous molecules like 7-dehydrocholesterol provide GPX4-independent protection. Cancer cells, with their elevated iron dependency and oxidative load, sit closer to this cliff edge than most healthy cells, which is precisely why ferroptosis has become such a magnetic therapeutic target.

Yet the review emphasizes that no tumor cell faces this cliff edge alone. The tumor microenvironment is a metabolic marketplace, and one of its most striking transactions involves cancer-associated fibroblasts. These stromal cells activate the TGF-β/SMAD3/ATF4 signaling axis, which upregulates sulfur transfer pathways and drives the secretion of cysteine into the tumor’s extracellular space. Tumor cells absorb this donated cysteine, convert it into glutathione, and keep GPX4 fully armed against lipid peroxidation. In pancreatic cancer, fibroblasts have been shown to reprogram cysteine metabolism in exactly this way, shielding malignant cells from ferroptosis and from the drugs that try to induce it. The result is a protective niche, a metabolic life-support system built by non-malignant cells, that allows tumor cells to survive oxidative stress that should have killed them. Interrupting this cross-feeding, the review argues, could strip away one of the most important layers of ferroptosis resistance in solid tumors.

Fibroblasts deploy other defenses as well. In gastric cancer, cancer-associated fibroblasts secrete exosomes carrying microRNA-522, which suppresses ferroptosis in neighboring tumor cells and promotes acquired resistance to chemotherapy. In ovarian cancer, the collagen receptor DDR2 confers ferroptosis resistance on the fibroblasts themselves and, in doing so, blunts the sensitivity of tumor cells to PARP inhibitors. Stromal lactic acid adds yet another shield: lactate produced in the acidic, hypoxic tumor core exerts an anti-ferroptotic effect on prostate carcinoma cells, an effect that can be neutralized by targeting the carbonic anhydrases IX and XII. Hypoxia itself reshapes lipid handling, inducing lipid droplet accumulation that sequesters oxidizable fatty acids away from membranes, and in hepatocellular carcinoma, hypoxia-driven USP13 expression stabilizes the enzyme ACLY, reinforcing ferroptosis resistance while simultaneously promoting immune evasion. The microenvironment, in short, is not a passive backdrop but an active pharmacological antagonist.

The immune dimension of this story is genuinely double-edged. On the promoting side, ferroptotic cancer cells can release damage-associated molecular patterns and oxidized lipid species that stimulate dendritic cells and enhance antigen cross-presentation, and ferroptosis signatures in head and neck cancer correlate with stronger responses to immune checkpoint inhibitors. CD8⁺ T cells themselves can push tumor cells toward ferroptosis: interferon-gamma released by these lymphocytes downregulates the cystine importer SLC7A11, and via the enzyme ACSL4, T cell-derived fatty acids help arm tumor membranes for peroxidation. Neutrophils have been shown to induce ferroptotic tumor necrosis in glioblastoma, and hybrid cell-death approaches that combine apoptosis and ferroptosis have potentiated PD-L1 blockade in preclinical models. In these contexts, inducing ferroptosis looks like a rational partner strategy for immunotherapy.

But the same pathway can be turned against the immune system. CD36-mediated uptake of fatty acids by intratumoral CD8⁺ T cells triggers ferroptosis-like lipid damage within the T cells themselves, dampening their effector function and weakening antitumor immunity. Cystine deprivation in the tumor core similarly triggers CD36-dependent ferroptosis and dysfunction in tumor-infiltrating CD8⁺ T cells. Tumors can also weaponize lipid biology defensively: in triple-negative breast cancer, tumor-derived arachidonic acid reprograms neutrophils into an immunosuppressive state that promotes therapy resistance. Whether ferroptosis ultimately stimulates or suppresses antitumor immunity depends on which cells die, how much they die, and in what microenvironmental context, a contingency that the review identifies as one of the field’s central unresolved questions and one that any clinical strategy must navigate carefully.

Metastasis adds a third layer of complexity. Epithelial-mesenchymal transition, the plasticity program that lets carcinoma cells detach and migrate, intersects with ferroptosis in paradoxical ways. The transcription factor ZEB1, a core EMT driver, actually renders cancer cells more ferroptosis-sensitive by reshaping lipogenic enzyme expression and membrane phospholipid composition, suggesting that migrating cells carry an internal combustibility that could be exploited therapeutically. Yet other survival programs counteract this vulnerability: clusters of detached gastric cancer cells suppress anoikis-linked ferroptosis to colonize distant sites, and exosome-mediated communication helps establish pre-metastatic niches. Colon cancer exosomes carrying HSP90B1, for example, polarize liver macrophages toward an M2 phenotype to prepare the hepatic soil for incoming seeds, while hypoxia-induced exosomal circ-ZNF609 and PRL-3-upregulated integrins promote pre-metastatic niche formation in esophageal and colon cancers respectively. Ferroptosis sensitivity, the review argues, is remodeled at every step of the metastatic cascade, and understanding those checkpoints may reveal when traveling tumor cells are most exposed.

Therapy resistance across modalities converges on these same mechanisms. Chemotherapy-resistant tumors frequently overexpress SLC7A11 and stockpile glutathione; gastric cancer cells resistant to cisplatin rely on the SLC7A11-AS1/xCT axis for glutathione-dependent survival. Cancer-associated fibroblasts promote EGFR-TKI resistance in lung cancer through a CTHRC1-driven glycolytic feedback loop, and exosomal miR-214-3p from fibroblasts inhibits ferroptosis to confer cisplatin resistance. Radiotherapy, which generates reactive oxygen species, would seem a natural ferroptosis sensitizer, yet hypoxic tumor regions and lipid droplet buffering blunt that effect. Even cancer stem cells, the recalcitrant reservoirs thought to seed relapse, manage iron and redox balance through CD44 and related regulators, and nanoplatforms that combine cholesterol modulation with ferroptosis induction are being engineered to break their resistance. The unifying insight is that resistance is rarely a single mutation; it is an ecosystem-level property maintained by the microenvironment.

The therapeutic pipeline reflects this systems perspective. Small molecules such as acevaltrate, which dual-targets PCBP1/2 and GPX4 in colorectal cancer, and FSP1 inhibitors that trigger ferroptosis in lung cancer are advancing the pharmacology beyond first-generation system Xc⁻ blockers. Nanotechnology offers spatial control: nanoparticles that synergize ferroptosis with cuproptosis to potentiate immunotherapy, bacteria-membrane-coated magnetic nanoparticles, hydrogen sulfide-powered nanomotors that disrupt the lactate-pyruvate axis, and sonocatalyst-enhanced supramolecular inducers all aim to deliver lethal lipid peroxidation precisely inside tumors. Biomarker efforts, including ferroptosis-based scoring systems such as FERscore for predicting inducer sensitivity in breast cancer and GPX4 as a pan-cancer immunotherapy biomarker, seek to match patients with the right combination. Estrogen-regulated system Xc⁻ targeting has even restored endocrine sensitivity in ER-positive breast cancer models.

The review’s overarching message is one of disciplined optimism. Ferroptosis is real, druggable, and deeply woven into tumor behavior, but it cannot be understood, or targeted, at the level of the isolated cancer cell. Every fibroblast-donated cysteine molecule, every exosomal microRNA, every lactate gradient, and every ferroptotic T cell shapes whether inducing lipid peroxidation heals the patient or backfires. Recent translational roadmaps in Nature Review journals echo the same conclusion: decoding ferroptosis for cancer therapy will require mapping its microenvironmental context as rigorously as its core enzymology. As clinical trials of ferroptosis inducers and their combinations mature, the tumors that ultimately yield may be those whose protective niches have been dismantled first, a strategy that turns the tumor’s own ecosystem from a fortress into a trap.

Subject of Research: The role of ferroptosis and the tumor microenvironment in cancer therapy resistance, immune evasion, and metastasis

Article Title: Ferroptosis and tumor microenvironment: orchestrating therapy resistance, immune evasion, and metastatic events

Article References: Ullah, M. F. (2026). Ferroptosis and tumor microenvironment: orchestrating therapy resistance, immune evasion, and metastatic events. Medical Oncology, 43(11), Article 307. https://doi.org/10.1007/s12032-026-03432-1

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03432-1

Keywords: ferroptosis, tumor microenvironment, GPX4, cancer-associated fibroblasts, lipid peroxidation, therapy resistance, immune evasion, metastasis, CD8+ T cells, exosomes, SLC7A11, cancer immunotherapy